SK Life Science, Inc. to Present 10 Posters with New Cenobamate Data, Including a Late-Breaker, at the 2025 American Epilepsy Society (AES) Annual Meeting

Barchart · 11/21/2025 07:04

PARAMUS, N.J. , Nov. 21, 2025 /PRNewswire/ -- SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., will present new data on cenobamate, an anti-seizure medication, at the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta, Georgia, December 5-9, 2025.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.